Olumiant (baricitinib) – Patient-Friendly Medicine Information (Australia)

Olumiant is a prescription medicine containing baricitinib, a medicine used to help control certain inflammatory conditions, including rheumatoid arthritis, active psoriatic arthritis, and some cases of moderate to severe atopic dermatitis and COVID-19 under specific clinical circumstances. This page explains how Olumiant works, how it behaves in the body, what it’s used for, and practical considerations for safe use.

Always follow the advice of your healthcare professional for your specific situation. This information is intended to be helpful and general.

At a glance

• Active ingredient: baricitinib
• Medicine class: Janus kinase (JAK) inhibitor
• How it’s taken: usually once daily by mouth (tablet strength varies)
• Common goals: reduce inflammation, improve symptoms, slow disease progression
• Key safety considerations: infections, blood tests (e.g., cholesterol, blood counts), clot/heart-risk discussion, liver and kidney monitoring

Basic product information

In Australia, Olumiant is supplied in tablet form. Strengths may include (depending on local supply) 1 mg and 2 mg tablets. Your exact dose will depend on the condition being treated and your individual risk factors.

Brand name: Olumiant
Generic name: baricitinib
Dosage form: oral tablet

How Olumiant works (mechanism of action)

Olumiant contains baricitinib, which inhibits signalling inside cells through enzymes called Janus kinase (JAK) pathways. These pathways are involved in the body’s immune and inflammatory responses.

By blocking specific JAK signals, baricitinib can help reduce the inflammatory cascade that contributes to symptoms such as:

• joint pain and swelling (e.g., rheumatoid arthritis)
• skin inflammation and itch (e.g., atopic dermatitis)
• immune-driven tissue damage over time

Pharmacokinetics (how it behaves in the body)

Pharmacokinetics describes what the body does to a medicine—absorption, distribution, metabolism, and excretion. Understanding these points can help you plan dosing and manage interactions.

Absorption and onset

• After taking by mouth, baricitinib is absorbed into the bloodstream.
• Peak levels typically occur within about 1–2 hours after a dose.
• Food generally has only limited effect on overall exposure, but individual advice may vary.

Distribution

• Baricitinib distributes through the body and works on immune-related signalling pathways.
• Protein binding and tissue distribution contribute to its effect lasting across the day.

Metabolism and elimination

• Baricitinib is partly cleared by the body’s metabolic processes and partly removed via kidneys.
• Because the kidneys play a role, dose adjustments may be needed for kidney impairment.

Practical takeaway: If you have kidney problems, your prescriber will usually consider kidney function tests to choose the safest dose.

Typical uses and conditions

Olumiant is used to treat certain inflammatory or immune conditions. The specific eligibility criteria can vary based on national guidance, regulatory approvals, and clinical assessment.

Commonly referenced indications

• Rheumatoid arthritis (RA): moderate to severe RA in adults, particularly when other treatments have not provided enough control.
• Active psoriatic arthritis: for certain adults where treatment is needed to control disease activity.
• Atopic dermatitis (AD): moderate to severe AD in selected adults and adolescents (age limits and criteria depend on local guidance).
• COVID-19: used in hospital settings for severe or critically ill patients under specific protocols (not for routine self-treatment at home).

If you are unsure whether your use of Olumiant matches an approved indication, ask your healthcare professional.

Timing and how to take Olumiant

Olumiant is usually taken once daily as a tablet. The exact dose (e.g., 1 mg vs 2 mg) depends on the condition and your health profile.

When to take it

• Try to take it at the same time each day to maintain consistent medicine levels.
• You can take it with or without food (see food interactions below for details).
• If you miss a dose, take it when you remember unless it’s close to the next dose—do not double up.

Swallowing tips

• Swallow the tablet with water.
• Do not crush or break the tablet unless advised by your pharmacist or the product instructions.

How long until it helps?

Many people begin to notice improvements within a few weeks, but the full benefit can take longer. Your healthcare professional will monitor progress using symptom review and, for some conditions, blood tests and physical assessments.

Important: Do not stop Olumiant suddenly without medical advice, even if you feel better.

Food interactions and eating considerations

In general, food has limited impact on baricitinib exposure. This means you can typically take Olumiant with or without meals.

Practical eating advice

• If your stomach feels sensitive, taking with food may feel more comfortable for some people.
• Maintain a normal, balanced diet to support overall health, especially when monitoring cholesterol and blood counts.

Alcohol and medicine interactions

There is no specific alcohol interaction that universally prohibits alcohol while taking baricitinib, but combining alcohol with any medicine can increase strain on the body and may affect how you feel or how your liver handles medications.

General guidance

• Moderate alcohol intake is often tolerated, but it’s best to keep intake limited.
• Avoid alcohol if you have liver problems or if you’ve been advised to minimise alcohol due to other medicines.
• If you develop unusual tiredness, abdominal discomfort, jaundice (yellowing), or dark urine—seek medical advice promptly.

When to be extra cautious

Be cautious if you also use other medications that can affect the liver (for example, some anti-inflammatories or immunosuppressants), or if you’ve had elevated liver enzymes.

Interactions with other medicines (and supplements)

Olumiant can interact with certain medicines, mainly because of its immune effects and because other drugs may influence how baricitinib is cleared. Tell your pharmacist and healthcare professional about everything you take, including over-the-counter products and supplements.

Examples of interaction categories

• Other JAK inhibitors: using more than one JAK inhibitor is generally not recommended.
• Strong enzyme inhibitors/inducers: some medicines can increase or decrease baricitinib levels.
• Immunosuppressants: combining multiple immune-modifying drugs may increase infection risk.
• Live vaccines: live vaccines may not be suitable during treatment—discuss vaccination timing with your healthcare professional.

Practical interaction checklist

• Keep an up-to-date list of your medicines and bring it to appointments.
• Ask before starting new medicines—especially antibiotics, antifungals, steroid dose changes, or strong herbal products.
• If you stop another medicine, ask whether your Olumiant dose should be adjusted.

Dose and administration (general information)

Dosing is individual. Your clinician will choose the most appropriate dose based on: the condition being treated, disease severity, age, kidney function, liver function, and infection risk.

Typical adult dosing (general reference)

Many adult regimens involve once-daily dosing. Depending on your condition and kidney function, your prescriber may use a 1 mg or 2 mg daily tablet schedule.

Kidney impairment: Dose adjustments are commonly required. If you have reduced kidney function, your clinician will use kidney tests to set the safest dose.

Children/adolescents: Dosing depends on age, weight, and indication; use only under specialist guidance.

Monitoring alongside dosing

• Blood tests for full blood count (e.g., neutrophils, lymphocytes, haemoglobin).
• Kidney function (e.g., creatinine/eGFR).
• Liver function tests.
• Lipid profile (cholesterol) may be checked.

Monitoring helps detect changes early and supports safe continued treatment.

Safety profile and important precautions

Like all medicines, Olumiant can cause side effects. Some effects are mild and manageable, while others require urgent medical attention. This section summarises key risks in plain language.

Common side effects

• Upper respiratory tract infections (e.g., common cold)
• Nausea or indigestion
• Headache
• Changes in blood tests (such as cholesterol increases)
• Lab abnormalities in blood counts (detected on routine monitoring)

Serious risks (seek medical advice promptly)

• Infections: because Olumiant affects the immune system, there is an increased risk of infections.
• Signs of infection: fever, chills, sore throat, shortness of breath, persistent cough, burning when urinating, skin sores, or unexplained fatigue.
• Unusual symptoms or severe infection: contact healthcare services urgently.
• Blood clots: any signs such as one-sided leg swelling/pain, chest pain, or sudden breathlessness should be treated as emergencies.
• Allergic reactions: swelling of the face/lips, hives, or difficulty breathing require urgent care.

Before starting (and during treatment)

Your healthcare professional may review the following before and while you’re on Olumiant:

• history of recurrent or serious infections
• tuberculosis (TB) screening, as recommended
• hepatitis screening, if appropriate
• current medications that increase infection risk
• baseline blood tests and ongoing monitoring

Vaccines

Live vaccines may not be recommended during treatment. Inactivated vaccines may still be possible but may have reduced effectiveness. Discuss vaccination plans early.

Practical use tips (how to get the best results safely)

• Attend monitoring: follow blood test schedules so dose and safety can be optimised.
• Watch infection signs: seek medical advice early rather than waiting.
• Keep a medicine record: note the dose, time taken, and any side effects.
• Maintain hygiene: regular hand washing and sensible precautions during outbreaks.
• Don’t stop abruptly: unless advised by your clinician, continuing as directed helps prevent flare-ups.
• Report new medicines: including antibiotics, antifungals, steroids, and supplements.

Alternative options

If you’re considering alternatives to Olumiant—or if your clinician decides a different approach is better—options vary by condition. Some alternatives include other targeted therapies, biologic medicines, corticosteroids (short-term for flares), and conventional disease-modifying medicines.

Examples of alternatives (by condition)

• Rheumatoid arthritis: conventional DMARDs (e.g., methotrexate), biologic DMARDs, and other targeted therapies.
• Psoriatic arthritis: DMARDs, biologics, and targeted agents depending on your pattern of disease.
• Atopic dermatitis: topical treatments, phototherapy, systemic non-JAK immunomodulators, and other biologic or targeted therapies.
• COVID-19 (hospital setting): specific inpatient treatment protocols; choices depend on disease severity and local guidelines.

Your healthcare professional can explain what is suitable for you and how risks/benefits compare.

Market and legal context in Australia (overview)

In Australia, medicines are regulated by the Australian Government’s medicines and healthcare products regulator (including the TGA framework). Access and use of baricitinib products such as Olumiant is governed by: therapeutic indications, prescribing rules, and ongoing safety monitoring.

Funding and reimbursement arrangements for certain conditions may involve national or state-based programs and eligibility criteria. These can change over time, so it’s useful to discuss access routes with your healthcare team and/or pharmacist.

Recent guidance and safety updates (general)

International and Australian health authorities have continuously reviewed data on JAK inhibitors, including updates related to infection risk, blood clot risk awareness, and the importance of monitoring blood tests and screening for tuberculosis when appropriate.

What this means for you: your healthcare professional may assess your personal risk factors and may recommend:

• baseline and periodic blood work
• prompt evaluation of infections
• review of cardiovascular/clot risk factors
• vaccination considerations

Because guidance can evolve, always rely on current instructions provided by your clinician and the most up-to-date product information.

Delivery and availability (online pharmacy information)

Availability of Olumiant can vary depending on dose strength and local supply conditions. If you’re ordering from an online pharmacy, availability timelines can depend on: tablet strength, stock on hand, and whether the item needs to be sourced from a supplier.

What you can expect

• Discreet packaging suitable for home delivery.
• Tracking options in many deliveries.
• Cold-chain handling is generally not required for tablets, but follow your pharmacy’s specific instructions.
• Processing times may differ on weekdays vs public holidays.

For the most accurate delivery estimate, check the live availability status on the pharmacy website or contact customer support.

FAQ

1) What is Olumiant used for?

Olumiant (baricitinib) is used to treat certain inflammatory conditions such as rheumatoid arthritis, active psoriatic arthritis, and moderate to severe atopic dermatitis in selected patients, and it may be used in specific hospital treatment pathways for COVID-19. The exact eligibility depends on the approved indication and your health profile.

2) How do I take Olumiant?

Typically it’s taken once daily by mouth, at about the same time each day. You can usually take it with or without food. If you miss a dose, follow your pharmacist’s guidance—commonly, don’t double up.

3) How quickly will I feel better?

Some people notice improvements within a few weeks, but full benefits can take longer. Regular check-ins and monitoring help determine whether the dose and treatment plan are working for you.

4) Can I take Olumiant with food?

Yes. Baricitinib can generally be taken with or without food. If food affects your comfort, taking it with meals may help.

5) Are there interactions with alcohol?

Alcohol doesn’t have a universal “must avoid” interaction, but moderation is advisable. If you have liver problems or take other medicines that may affect the liver, discuss alcohol with your healthcare professional.

6) What medicines should I avoid?

Avoid or carefully review medicines that may increase infection risk or affect baricitinib levels. Tell your pharmacist about all medicines (including over-the-counter products, vitamins, and herbal supplements).

7) What are the most important side effects?

The most important potential risks include infections and other serious reactions. Contact a healthcare professional urgently if you develop signs of infection (such as fever or persistent cough), symptoms of blood clots (such as sudden breathlessness or one-sided leg swelling), or signs of an allergic reaction.

8) Will I need blood tests?

Yes. Routine monitoring is important for safety and dose optimisation. This may include blood counts, kidney function, liver function, and cholesterol levels.

9) Can I get vaccinated while on Olumiant?

Vaccine advice depends on the type of vaccine and your health situation. Live vaccines may be unsuitable during treatment. Ask your healthcare professional for guidance about timing and vaccine choice.

10) What if I get an infection?

If you suspect an infection, contact your healthcare professional promptly. Don’t ignore symptoms, especially fever or respiratory symptoms. Your clinician will advise whether you should continue, pause, or adjust treatment.

11) What are alternative treatments if Olumiant isn’t suitable?

Alternatives vary by condition and may include other DMARDs, biologic therapies, topical/systemic treatments, or other targeted medicines. Your healthcare professional can help match the best option to your disease type and risk profile.

Quick-reference safety table

Summary

Olumiant (baricitinib) is a JAK inhibitor used to reduce immune-driven inflammation in conditions such as rheumatoid arthritis, active psoriatic arthritis, and moderate to severe atopic dermatitis in selected patients. It works by interfering with immune signalling pathways and may improve symptoms and help control disease activity. As with all immune-modulating medicines, safety monitoring is important—especially for infection risk and changes seen in blood tests.

If you have questions about whether Olumiant is appropriate for your condition, or how to take it safely alongside your other medicines, speak with your healthcare professional or pharmacist.